
Albertsons Companies (ACI) Stock Forecast & Price Target
Albertsons Companies (ACI) Analyst Ratings
Bulls say
Albertsons Companies has demonstrated steady financial growth, with net sales revenue increasing by 2.08% year-over-year to $81.37 billion for the 12 months ending August 2025 and Q2 2026 revenue reflecting a similar upward trend, rising 2% year-over-year to $18.92 billion. The company's comp sales grew by 2.2%, driven by strong performances in non-perishables and pharmacy sales, the latter spiking 19% year-over-year due to increased prescription volumes and the demand for GLP-1 treatments. Additionally, booming digital sales, which surged by 21% in Q3 2025, indicate robust customer engagement, positioning Albertsons favorably for future market growth amid developing e-commerce and fulfillment capabilities.
Bears say
Albertsons Companies has experienced a decline in key financial metrics, highlighting concerns about its profitability and operational efficiency. Specifically, the gross margin decreased by 60 basis points to 27%, primarily due to higher digital fulfillment costs and a greater reliance on lower-margin pharmacy revenues. Additionally, Year-over-Year declines in Net Operating Profit After Tax (NOPAT) by 3.53% and Economic Profit (EP) by 29.28% further signal a challenging economic environment and diminishing returns on investments, raising doubts about the company's financial health.
This aggregate rating is based on analysts' research of Albertsons Companies and is not a guaranteed prediction by Public.com or investment advice.
Albertsons Companies (ACI) Analyst Forecast & Price Prediction
Start investing in Albertsons Companies (ACI)
Order type
Buy in
Order amount
Est. shares
0 shares